J
John R. Strawn
Researcher at New York University
Publications - 11
Citations - 4702
John R. Strawn is an academic researcher from New York University. The author has contributed to research in topics: Lung cancer & Guideline. The author has an hindex of 10, co-authored 10 publications receiving 4452 citations. Previous affiliations of John R. Strawn include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
David G. Pfister,David H. Johnson,Christopher G. Azzoli,William Sause,Thomas J. Smith,Sherman Baker,Jemi Olak,Diane Stover,John R. Strawn,Andrew T. Turrisi,Mark R. Somerfield +10 more
TL;DR: The American Society of Clinical Oncology (ASCO) previously published evidence-based guidelines for the treatment of unresectable non-small-cell lung cancer (NSCLC) as discussed by the authors.
Journal ArticleDOI
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli,Sherman Baker,Sarah Temin,William Pao,Timothy Aliff,Julie R. Brahmer,David H. Johnson,Janessa L. Laskin,Gregory A. Masters,Daniel T. Milton,Luke Nordquist,David G. Pfister,Steven Piantadosi,Joan H. Schiller,Reily Smith,Thomas J. Smith,John R. Strawn,David Trent,Giuseppe Giaccone +18 more
TL;DR: The scope of the guideline was narrowed to chemotherapy and biologic therapy, and recommendations for the treatment of patients with stage IV non-small-cell lung cancer were updated.
Journal ArticleDOI
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Gregory A. Masters,Sarah Temin,Christopher G. Azzoli,Giuseppe Giaccone,Sherman Baker,Julie R. Brahmer,Peter M. Ellis,Ajeet Gajra,Nancy Rackear,Joan H. Schiller,Thomas J. Smith,John R. Strawn,David Trent,David H. Johnson +13 more
TL;DR: This guideline update reflects changes in evidence since the previous guideline and recommends combination cytotoxic chemotherapy is recommended, guided by histology, with early concurrent palliative care.
Journal ArticleDOI
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki L. Keedy,Sarah Temin,Mark R. Somerfield,Mary Beth Beasley,David H. Johnson,Lisa M. McShane,Daniel T. Milton,John R. Strawn,Heather A. Wakelee,Giuseppe Giaccone +9 more
TL;DR: The clinical utility of using epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer to predict the benefit of taking a first-line EGFR tyrosine kinase inhibitor (TKI) is addressed.
Journal ArticleDOI
Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline
Katherine M.W. Pisters,William K. Evans,Christopher G. Azzoli,Mark G. Kris,Christopher A. Smith,Christopher E. Desch,Mark R. Somerfield,Melissa C. Brouwers,Gail Darling,Peter M. Ellis,Laurie E. Gaspar,Harvey I. Pass,David R. Spigel,John R. Strawn,Yee C. Ung,Frances A. Shepherd +15 more
TL;DR: Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA disease, and adjuvant radiation therapy appears detrimental to survival in stage IB and II, and may possibly confer a modest benefit in stage IIIA.